Kathleen Goin

COO Kathleen Goin sold 4,302 shares ($642,191.48) via 10b5-1 plan; retains 12,917 derivative options.

Kathleen Goin, Chief Operating Officer, executed four separate sales on 2026-07-15 totaling 4,302 shares for $642,191.48 at an average price of $149.28 per share. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-08-19 and therefore scheduled rather than discretionary. Although the Form 4 shows zero non-derivative shares post-transaction, the insider retains 12,917 shares through derivative securities (stock options), indicating a maintained equity stake in the company. Looking at SAME-TICKER HISTORY, her five prior sales at PVLA between April and July 2026 each generated negative 30-day returns (ranging from -9.3% to -12.4%) followed by positive 90-day returns (+14.8% to +18.8%), a pattern suggesting the stock has historically recovered within three months following her sales. The company is currently unprofitable (net income of $-15,767,000.00 on zero revenue this quarter) despite annual revenue growth of +65.3%, and the stock has appreciated +39.6% over the past 30 days and +20.9% over 90 days—context that frames this as a scheduled liquidation of a non-derivative tranche rather than a conviction-driven trade.

COO Kathleen Goin sells entire 4,302-share position for $547,398.98 via 10b5-1 plan adopted 2025-08-19

Kathleen Goin, Chief Operating Officer of Palvella Therapeutics, executed 5 separate sales on 2026-04-15 totaling 4,302 shares for $547,398.98 at prices ranging from $125.96 to $130.33 per share, liquidating her entire holdings to zero. This transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on 2025-08-19, meaning the sales were scheduled and not discretionary. The complete exit of the COO's position represents a material change in insider ownership stake, though the pre-arranged nature limits inference about current conviction. Investors should track whether other executives maintain or alter their positions and monitor company performance relative to the sale price range ($125.96–$130.33).

COO Kathleen Goin liquidates entire 4,302-share holding via 3 sales for $507,610.99 under 10b5-1 plan

Kathleen Goin, Chief Operating Officer, executed 3 separate sales totaling 4,302 shares for $507,610.99 on 2026-03-18, eliminating her entire shareholding post-transaction (net change: -100.0% vs pre-transaction holdings). The transactions were executed at prices ranging from $117.56 to $119.08, with a blended average price of $117.99. This sale is part of a pre-arranged 10b5-1 trading plan adopted on 2025-08-19, meaning it was scheduled rather than discretionary. Complete liquidation of an executive's holdings warrants investor attention as a potential signal, though the scheduled nature of the trades via a pre-arranged plan removes timing-based inference.